Expression and clinical significance of contactin-1 in patients with primary lung squamous cell carcinoma

doi:10.3877/cma.j.issn.1674-6902.2020.02.003

Abstract

Abstract:

Objective

To investigate the expression of contactin-1 (CNTN-1) in the patients with primary lung squamous cell carcinoma and to explore the relationship between the CNTN-1 expression and the clinical pathologic parameters.

Methods

The expression levels of CNTN-1 in the tumor tissues from 63 patients with primary lung squamous cell carcinoma and 20 human samples with normal lung epithelial tissues were analyzed by immunohistochemistry.

Results

In 63 primary lung squamous cell carcinoma tissue samples, 35 cases with positive expression, 26 cases with negative expression, 2 cases invalid, CNTN-1 expressed in the primary lung squamous cell carcinoma tissues with a positive rate of 55.65%, while it was undetectable in the normal human lung epithelial tissues. Moreover, the positive staining of CNTN-1 was found to be significantly correlated with the smoking history (P<0.05) and the lymphatic invasion before surgery (P<0.05). However, no significant difference was found between the levels of CNTN-1 expression and the clinical pathologic parameters of the patients with primary lung squamous cell carcinoma.

Conclusion

CNTN-1 might be a potential biomarker to predict the prognosis of the patients with primary lung squamous cell carcinoma.

Key words: Primary lung squamous cell carcinoma, Contactin-1, Immunohistochemistry, Iymphatic invasion

Ruijie Zhang, Fuyun Ji, Guisheng Qian, Shilong Yu, Daoxin Wang. Expression and clinical significance of contactin-1 in patients with primary lung squamous cell carcinoma[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(02): 139-143.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.02.003

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I02/139

Figures/Tables 3

References 24

1	钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2	Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer[J]. Ann Glob Health, 2019, 22, 85(1): pii: 8.
3	Luo X, Zhao X, Cheng C, et al. The implications of signaling lipids in cancer metastasis[J]. Exp Mol Med, 2018, 50(9): 127.
4	Berglund EO, Ranscht B. Molecular cloning and in situ localization of the human contactin gene (CNTN1) on chromosome 12q11-q12[J]. Genomics, 1994, 21(3): 571-582.
5	Su JL, Yang CY, Shih JY, et al. Knockdown of contactin-1 expression suppresses invasion and metastasis of lung adenocarcinoma[J]. Cancer Res, 2006, 79(14): 3793.
6	Liu P, Zhou J, Zhu H, et al. VEGF-C promotes the development of esophageal cancer via regulating CNTN-1 expression[J]. Cytokine, 2011, 55(1): 8-17.
7	Liu PF, Chen SM, Wu WT, et al. Contactin-1(CNTN-1) overexpression is correlated with advanced clinical stage and lymph node metastasis in oesophageal squamous cell carcinomas[J]. Jpn J Clin Oncol, 2012, 42(7): 612-618.
8	Yu JW, Wu SH, Lu RQ, et al. Expression and significances of contactin-1 in human gastric cancer[J]. Gastroenterol Res Pract, 2013, 2013: 210205.
9	Wu HM, Cao W, Ye DX, et al. Contactin 1 (CNTN1) expression associates with regional lymph node metastasis and is a novel predictor of prognosis in patients with oral squamous cell carcinoma[J]. Mol Med Rep, 2012, 6(2): 265-270.
10	Chen N, He S, Geng J, et al. Overexpression of contactin 1 promotes growth, migration and invasion in Hs578T breast cancer cells[J]. BMC cell biology, 2018, 19(1): 5.
11	Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines insights：non-small cell lung cancer, version 5.2018[J]. J Natl Compr Canc Netw, 2018, 16(7): 807-821.
12	Mehta R, Kyshtoobayeva A, Kurosaki T, et al. Independent association of angiogenesis index with outcome in prostate cancer[J]. Clin Cancer Res, 2001, 7(1): 81-88.
13	Bernicker EH, Allen TC, Cagle PT. Update on emerging biomarkers in lung cancer[J]. J Thorac Dis, 2019, 11(Suppl 1): S81-S88.
14	Yang J, Yu F, Guan J, et al. Knockdown of RNF2 enhances radiosensitivity of squamous cell carcinoma cells in lung[J]. Biochem Cell Biol, 2019, 97(5): 589-599.
15	Chen J, Wu Y, Zhang L, et al. Evidence for calpains in cancer metastasis[J]. J Cell Physiol, 2019, 234(6): 8233-8240.
16	Revest JM, Faivre-Sarrailh C, Maeda N, et al. The interaction between F3 immunoglobulin domains and protein tyrosine phosphatases zeta/beta triggers bidirectional signalling between neurons and glial cells[J]. Eur J Neurosci, 1999, 11(4): 1134-1147.
17	Bizzoca A, Virgintino D, Lorusso L, et al. Transgenic mice expressing F3/contactin from the TAG-1 promoter exhibit developmentally regulated changes in the differentiation of cerebellar neurons[J]. Development, 2003, 130(1): 29-43.
18	Compton AG, Albrecht DE, Seto JT, et al. Mutations in contactin-1, a neural adhesion and neuromuscular junction protein, cause a familial form of lethal congenital myopathy[J]. Am J Hum Genet., 2008, 83: 714-724.
19	Chen YA, Lu IL, Tsai JW. Contactin-1/F3 regulates neuronal migration and morphogenesis through modulating rhoA activity[J]. Front Mol Neurosci, 2018, 11: 422.
20	Su JL, Yang PC, Shih JY, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells[J]. Cancer cell, 2006, 9(3): 209-223.
21	Hung YH, Hung WC. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) enhances invasiveness of lung cancer cells by up-regulating contactin-1 via the alpha7 nicotinic acetylcholine receptor/ERK signaling pathway[J]. Chem Biol Interact, 2009, 179(2-3): 154-159.
22	吴生华，俞继卫，郑林海，等. CNTN-1、VEGF-C和VEGFR-3在胃癌组织中的表达及其临床意义[J]. 中国普外基础与临床杂志，2011, 18(2): 142-148.
23	Liu P, Chen S, Wu W, et al. Contactin-1(CNTN-1) overexpression is correlated with advanced clinical stage and lymph node metastasis in oesophageal squamous cell carcinomas[J]. Jpn J Clin Oncol, 2012, 42(7): 612-618.
24	Wu HM, Cao W, Ye D, et al. Contactin 1 (CNTN1) expression associates with regional lymph node metastasis and is a novel predictor of prognosis in patients with oral squamous cell carcinoma[J]. Mol Med Rep, 2012, 6(2): 265-270.

临床资料及病理参数		例数	CNTN-1表达		切片无肿瘤组织	P值^c
临床资料及病理参数		例数	阴性	阳性	切片无肿瘤组织	P值^c
性别						0.112^a
	男性	56(88.89)	25(44.64)	29(51.79)	2(3.57)
	女性	7(11.11)	1(14.29)	6(85.71)	0(0.00)
患病年龄(岁)						0.126^a
	≤60	39(61.90)	14(35.90)	25(64.10)	0(0.00)
	>60	24(38.10)	12(50.00)	10(41.67)	2(8.33)
吸烟年包数(包)^b						0.027^a
	0～30	42(66.67)	13(30.95)	27(64.29)	2 (4.76)
	>30	21(33.33)	13(61.90)	8(38.10)	0(0.00)
肿瘤组织分化级别						0.634^a
	高分化	4(6.35)	1(25.00)	1(25.00)	2(50.00)
	中分化	18(28.57)	6(33.33)	12(66.67)	0(0.00)
	低分化	41(65.08)	19(46.34)	22(53.66)	0(0.00)
肿瘤TNM分期						0.499^a
	Ⅰ期	41(65.08)	18(43.90)	21(51.22)	2(4.88)
	Ⅱ期	11(17.46)	4(36.36)	7(63.64)	0(0.00)
	Ⅲ期	10(15.87)	3 (30.00)	7(70.00)	0(0.00)
	Ⅳ期	1(1.59)	1(100.00)	0(0.00)	0(0.00)
术前淋巴结侵袭						0.010^a
	(+)	22(34.92)	4(18.18)	18(81.82)	0(0.00)
	(-)	40(63.49)	21(52.50)	17(42.50)	2(5.00)
	失访例数	1(1.59)	1(100.00)	0(0.00)	0(0.00)
术后淋巴结侵袭						0.104^a
	(+)	9(14.29)	1(11.11)	8(88.89)	0(0.00)
	(-)	44(69.84)	20(45.45)	23(52.27)	1(2.27)
	失访例数	10(15.87)	5(50.00)	4(40.00)	1(10.00)
区域性转移						0.471^a
	(+)	8(12.70)	5(62.50)	3(37.50)	0(0.00)
	(-)	46(73.02)	18(39.13)	27(58.70)	1(2.17)
	失访例数	9(14.29)	3(33.33)	5(55.59)	1(11.11)
复发						0.888^a
	(+)	6(9.52)	2(33.33)	4(66.67)	0(0.00)
	(-)	47(74.60)	20(42.55)	26(55.32)	1(2.13)
	失访例数	10(15.87)	4(40.00)	5(50.00)	1(10.00)
术后肿瘤组织大小变化^d						0.897^a
	肿瘤清除	35(55.56)	16(45.71)	19(54.29)	0(0.00)
	残余肿瘤无改变	11(17.46)	4(36.36)	7(63.64)	0(0.00)
	残余肿瘤增大	5(7.94)	2(40.00)	3(60.00)	0(0.00)
	残余肿瘤缩小	2(3.17)	0(0.00)	1(50.00)	1(50.00)
	失访例数	10(15.87)	4(40.00)	5(50.00)	1(10.00)

临床资料及病理参数		例数	CNTN-1表达		切片无肿瘤组织	P值^c
临床资料及病理参数		例数	阴性	阳性	切片无肿瘤组织	P值^c
性别						0.112^a
	男性	56(88.89)	25(44.64)	29(51.79)	2(3.57)
	女性	7(11.11)	1(14.29)	6(85.71)	0(0.00)
患病年龄(岁)						0.126^a
	≤60	39(61.90)	14(35.90)	25(64.10)	0(0.00)
	>60	24(38.10)	12(50.00)	10(41.67)	2(8.33)
吸烟年包数(包)^b						0.027^a
	0～30	42(66.67)	13(30.95)	27(64.29)	2 (4.76)
	>30	21(33.33)	13(61.90)	8(38.10)	0(0.00)
肿瘤组织分化级别						0.634^a
	高分化	4(6.35)	1(25.00)	1(25.00)	2(50.00)
	中分化	18(28.57)	6(33.33)	12(66.67)	0(0.00)
	低分化	41(65.08)	19(46.34)	22(53.66)	0(0.00)
肿瘤TNM分期						0.499^a
	Ⅰ期	41(65.08)	18(43.90)	21(51.22)	2(4.88)
	Ⅱ期	11(17.46)	4(36.36)	7(63.64)	0(0.00)
	Ⅲ期	10(15.87)	3 (30.00)	7(70.00)	0(0.00)
	Ⅳ期	1(1.59)	1(100.00)	0(0.00)	0(0.00)
术前淋巴结侵袭						0.010^a
	(+)	22(34.92)	4(18.18)	18(81.82)	0(0.00)
	(-)	40(63.49)	21(52.50)	17(42.50)	2(5.00)
	失访例数	1(1.59)	1(100.00)	0(0.00)	0(0.00)
术后淋巴结侵袭						0.104^a
	(+)	9(14.29)	1(11.11)	8(88.89)	0(0.00)
	(-)	44(69.84)	20(45.45)	23(52.27)	1(2.27)
	失访例数	10(15.87)	5(50.00)	4(40.00)	1(10.00)
区域性转移						0.471^a
	(+)	8(12.70)	5(62.50)	3(37.50)	0(0.00)
	(-)	46(73.02)	18(39.13)	27(58.70)	1(2.17)
	失访例数	9(14.29)	3(33.33)	5(55.59)	1(11.11)
复发						0.888^a
	(+)	6(9.52)	2(33.33)	4(66.67)	0(0.00)
	(-)	47(74.60)	20(42.55)	26(55.32)	1(2.13)
	失访例数	10(15.87)	4(40.00)	5(50.00)	1(10.00)
术后肿瘤组织大小变化^d						0.897^a
	肿瘤清除	35(55.56)	16(45.71)	19(54.29)	0(0.00)
	残余肿瘤无改变	11(17.46)	4(36.36)	7(63.64)	0(0.00)
	残余肿瘤增大	5(7.94)	2(40.00)	3(60.00)	0(0.00)
	残余肿瘤缩小	2(3.17)	0(0.00)	1(50.00)	1(50.00)
	失访例数	10(15.87)	4(40.00)	5(50.00)	1(10.00)

临床资料及病理参数		例数	阴性	CNTN-1表达阳性			切片无肿瘤组织	P值^c
临床资料及病理参数		例数	阴性	低表达	中等表达	高表达	切片无肿瘤组织	P值^c
性　别								0.084^a
	男性	56(88.89)	25(44.64)	9(16.07)	17(30.36)	3(5.36)	2(3.57)
	女性	7(11.11)	1(14.29)	4(57.14)	2(28.57)	0(0.00)	0(0.00)
患病年龄(岁)								0.552^a
	≤60	39(61.90)	14(35.90)	9(23.08)	14(35.90)	2(5.13)	0(0.00)
	>60	24(38.10)	12(50.00)	4(16.67)	5(20.83)	1(4.17)	2(8.33)
吸烟年包数(包)^b								0.053^a
	0～30	42(66.67)	13(30.95)	8(19.05)	17(40.48)	2(4.76)	2(4.76)
	>30	21(33.33)	13(61.90)	5(23.81)	2(9.52)	1(4.76)	0(0.00)
肿瘤组织分化级别								0.452^a
	高分化	4(6.35)	1(25.00)	1(25.00)	0(0.00)	0(0.00)	2(50.00)
	中分化	18(28.57)	6(33.33)	2(11.11)	9(50.00)	1(5.56)	0(0.00)
	低分化	41(65.08)	19(46.34)	10(24.39)	10(24.39)	2(4.88)	0(0.00)
肿瘤TNM分期								0.924^a
	Ⅰ期	41(65.08)	18(43.90)	8(19.51)	12(29.27)	1(2.44)	2(4.88)
	Ⅱ期	11(17.46)	4(36.36)	3(27.27)	3(27.27)	1(9.09)	0(0.00)
	Ⅲ期	10(15.87)	3(30.00)	2(20.00)	4(40.00)	1(10.00)	0(0.00)
	Ⅳ期	1(1.59)	1(100.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
术前淋巴结侵袭								0.139^a
	(+)	22(34.92)	4(18.18)	7(31.81)	9(40.91)	2(9.09)	0(0.00)
	(-)	40(63.49)	21(52.50)	6(15.00)	10(25.00)	1(2.50)	2(5.00)
	失访例数	1(1.59)	1(100.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
术后淋巴结转移^d								0.287^a
	(+)	9(14.29)	1(11.11)	4(44.44)	4(44.44)	0(0.00)	0(0.00)
	(-)	44(69.84)	20(45.45)	7(15.91)	13(29.55)	3(6.82)	1(2.27)
	失访例数	10(15.87)	5(50.00)	2(20.00)	2(20.00)	0(0.00)	1(10.00)
区域性转移								0.515^a
	(+)	8(12.70)	5(62.50)	2(25.00)	0(0.00)	1(12.50)	0(0.00)
	(-)	46(73.02)	18(39.13)	9(19.57)	16(34.78)	2(4.35)	1(2.17)
	失访例数	9(14.29)	3(33.33)	2(22.22)	3(33.33)	0(0.00)	1(11.11)
复发								0.319^a
	(+)	6(9.52)	2(33.33)	3(50.00)	0(0.00)	1(16.67)	0(0.00)
	(-)	47(74.60)	20(42.55)	8(17.02)	16(34.04)	2(4.26)	1(2.13)
	失访例数	10(15.87)	4(40.00)	2(20.00)	3(30.00)	0(0.00)	1(10.00)
术后肿瘤组织大小变化^d								0.636^a
	肿瘤清除	35(55.56)	16(45.71)	5(14.29)	12(34.29)	2(5.71)	0(0.00)
	残余肿瘤无变化	11(17.46)	4(36.36)	3(27.27)	3(27.27)	1(9.09)	0(0.00)
	残余肿瘤增大	5(7.94)	2(40.00)	3(60.00)	0(0.00)	0(0.00)	0(0.00)
	残余肿瘤缩小	2(3.17)	0(0.00)	0(0.00)	1(50.00)	0(0.00)	1(50.00)
	失访例数	10(15.87)	4(40.00)	2(20.00)	3(30.00)	0(0.00)	1(10.00)

临床资料及病理参数		例数	阴性	CNTN-1表达阳性			切片无肿瘤组织	P值^c
临床资料及病理参数		例数	阴性	低表达	中等表达	高表达	切片无肿瘤组织	P值^c
性　别								0.084^a
	男性	56(88.89)	25(44.64)	9(16.07)	17(30.36)	3(5.36)	2(3.57)
	女性	7(11.11)	1(14.29)	4(57.14)	2(28.57)	0(0.00)	0(0.00)
患病年龄(岁)								0.552^a
	≤60	39(61.90)	14(35.90)	9(23.08)	14(35.90)	2(5.13)	0(0.00)
	>60	24(38.10)	12(50.00)	4(16.67)	5(20.83)	1(4.17)	2(8.33)
吸烟年包数(包)^b								0.053^a
	0～30	42(66.67)	13(30.95)	8(19.05)	17(40.48)	2(4.76)	2(4.76)
	>30	21(33.33)	13(61.90)	5(23.81)	2(9.52)	1(4.76)	0(0.00)
肿瘤组织分化级别								0.452^a
	高分化	4(6.35)	1(25.00)	1(25.00)	0(0.00)	0(0.00)	2(50.00)
	中分化	18(28.57)	6(33.33)	2(11.11)	9(50.00)	1(5.56)	0(0.00)
	低分化	41(65.08)	19(46.34)	10(24.39)	10(24.39)	2(4.88)	0(0.00)
肿瘤TNM分期								0.924^a
	Ⅰ期	41(65.08)	18(43.90)	8(19.51)	12(29.27)	1(2.44)	2(4.88)
	Ⅱ期	11(17.46)	4(36.36)	3(27.27)	3(27.27)	1(9.09)	0(0.00)
	Ⅲ期	10(15.87)	3(30.00)	2(20.00)	4(40.00)	1(10.00)	0(0.00)
	Ⅳ期	1(1.59)	1(100.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
术前淋巴结侵袭								0.139^a
	(+)	22(34.92)	4(18.18)	7(31.81)	9(40.91)	2(9.09)	0(0.00)
	(-)	40(63.49)	21(52.50)	6(15.00)	10(25.00)	1(2.50)	2(5.00)
	失访例数	1(1.59)	1(100.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)
术后淋巴结转移^d								0.287^a
	(+)	9(14.29)	1(11.11)	4(44.44)	4(44.44)	0(0.00)	0(0.00)
	(-)	44(69.84)	20(45.45)	7(15.91)	13(29.55)	3(6.82)	1(2.27)
	失访例数	10(15.87)	5(50.00)	2(20.00)	2(20.00)	0(0.00)	1(10.00)
区域性转移								0.515^a
	(+)	8(12.70)	5(62.50)	2(25.00)	0(0.00)	1(12.50)	0(0.00)
	(-)	46(73.02)	18(39.13)	9(19.57)	16(34.78)	2(4.35)	1(2.17)
	失访例数	9(14.29)	3(33.33)	2(22.22)	3(33.33)	0(0.00)	1(11.11)
复发								0.319^a
	(+)	6(9.52)	2(33.33)	3(50.00)	0(0.00)	1(16.67)	0(0.00)
	(-)	47(74.60)	20(42.55)	8(17.02)	16(34.04)	2(4.26)	1(2.13)
	失访例数	10(15.87)	4(40.00)	2(20.00)	3(30.00)	0(0.00)	1(10.00)
术后肿瘤组织大小变化^d								0.636^a
	肿瘤清除	35(55.56)	16(45.71)	5(14.29)	12(34.29)	2(5.71)	0(0.00)
	残余肿瘤无变化	11(17.46)	4(36.36)	3(27.27)	3(27.27)	1(9.09)	0(0.00)
	残余肿瘤增大	5(7.94)	2(40.00)	3(60.00)	0(0.00)	0(0.00)	0(0.00)
	残余肿瘤缩小	2(3.17)	0(0.00)	0(0.00)	1(50.00)	0(0.00)	1(50.00)
	失访例数	10(15.87)	4(40.00)	2(20.00)	3(30.00)	0(0.00)	1(10.00)

[1]	Yang Zhao, Yingcong Xiao, Yan Ju, Xiaozhi Dang, Linli Cai, Wenxin Xue, Yang Li, Yao Xiao, Yuqi Guo, Hongping Song. Clinical value of automated breast ultrasound combined with immunohistochemistry in early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(04): 361-369.
[2]	Zhuangzhuang Wu, Xiaojuan Zhang, Zehong Shi, yao Shi, Shaoling Yuan. Prognostic value of ultrasound combined with mammography and PR and HER-2 status in high-grade and middle-low-grade ductal carcinoma in situ of the breast [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(06): 631-635.
[3]	Yuanyuan He, Jia Li, Hong Yang. Mesonephric adenocarcinoma of uterine cervix: a case report and literature review [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(01): 97-104.
[4]	Xingchen Liu, Juan Liu, Baobao Wei, Jie Liu, Hui Liu. Correlation analysis of abnormal expression of XIAP and XAF1 with ovarian cancer [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 419-427.
[5]	Chunying Han, Tingting Wang, Yanyan Li, Jinxia Piao. Current research status on predictors of lymphatic vascular invasion in patients with endometrial carcinoma [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 403-409.
[6]	Yifang Chen, Xiaohui Huang. Expression and clinical significance of paraoxonase 2 in hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(03): 186-191.
[7]	Weilin Guo, Yuntao Li, Peizhong Shang, Xiaowu Li, Wei Li. Expression of S100A4 and Midkine in pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 149-152.
[8]	Kun Jiao, Xiaoju Chen, Jing Lu. Pathological evaluation of animal experiments with intraperitoneal abdominal hernia repair [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2022, 16(06): 628-633.
[9]	Junfeng Li, Jun Li, Qinfeng Sun, Jianguang Sun, Xiangxing Kong. Clinicopathological features of 9 cases of colorectal medullary carcinoma [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(03): 248-252.
[10]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[11]	Wenbo Niu, Fengpeng Wu, Yueping Liu, Chaoxi Zhou, Juan Zhang, Xuhua Hu, Baokun Li, Gueying Wang. Neoadjuvant chemoradiotherapy for treatment of locally advanced rectal cancer: Efficacy and tumor immune microenvironment changes [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 519-523.
[12]	Quan Wang, Yingmei Zhou, Ying He. Clinical significance of expression of p27 and cyclin E in endometriosis [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(06): 546-552.
[13]	Gaocai Mao, Jianbo Zhang, Yifang Yuan, Xiaobo Mao, Huiyong Dai, Zhe Wang. Diagnostic characteristics of clear cell type oxyphilic adenoma of salivary gland in retroauricular lymph nodes [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(04): 261-265.
[14]	Ying Liu, Man Yin, Linqing Yang, Yunfei Wang. Diagnostic characteristics of invasive stratified mucin-producing carcinoma and literature review [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(03): 173-177.
[15]	Xiaoyun Lu, Shuhan Yu, Zeyu Wu, Qide Zhang, Peiyao Wu. Expression and clinical significance of CCR2, CCL2 and Foxp3 in colon cancer [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2023, 10(01): 52-56.

Please choose a citation manager

Content to export